Transmitted HIV Drug Resistance in Bulgaria Occurs in Clusters of Individuals from Different Transmission Groups and Various Subtypes (2012–2020)
暂无分享,去创建一个
M. Nikolova | W. Switzer | A. Shankar | I. Alexiev | R. Grozdeva | D. Strashimirov | N. Yancheva | Lyubomira Grigorova | Reneta Dimitrova | A. Gancheva | Asya Kostadinova | I. Baltadzhiev | R. Emilova | M. Stoycheva | I. Elenkov | L. Pekova | Yi Pan | Alexandra Partsuneva | T. Doichinova | Minas Kosmidis | L. Grigorova | Tsetsa Doichinova
[1] M. Poljak,et al. HIV-1 subtype B spread through cross-border clusters in the Balkans: a molecular analysis in view of incidence trends , 2022, AIDS.
[2] R. Paredes,et al. Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters , 2022, Frontiers in Microbiology.
[3] M. Salemi,et al. Analysis of the Origin and Dissemination of HIV-1 Subtype C in Bulgaria , 2022, Viruses.
[4] B. Foley,et al. Origin and evolution of HIV-1 subtype A6 , 2021, PloS one.
[5] S. Lyss,et al. Response to a Large HIV Outbreak, Cabell County, West Virginia, 2018-2019. , 2021, American journal of preventive medicine.
[6] Philip L. Tzou,et al. Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance , 2021, Viruses.
[7] M. Kantzanou,et al. Transmitted Drug Resistance among HIV-1 drug-naïve patients in Greece. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[8] Ellsworth M. Campbell,et al. Molecular Epidemiological Analysis of the Origin and Transmission Dynamics of the HIV-1 CRF01_AE Sub-Epidemic in Bulgaria , 2021, Viruses.
[9] L. Mbuagbaw,et al. Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis , 2020, The Journal of infectious diseases.
[10] P. Volberding,et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. , 2020, JAMA.
[11] R. Shafer,et al. HIV‐1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates , 2020, Journal of the International AIDS Society.
[12] M. Tsai,et al. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. , 2020, The Journal of antimicrobial chemotherapy.
[13] Sergey Knyazev,et al. MicrobeTrace: Retooling molecular epidemiology for rapid public health response , 2020, bioRxiv.
[14] M. Nikolova,et al. MOLECULAR EPIDEMIOLOGICAL ANALYSIS OF THE TRANSMISSION CLUSTERS OF THE HIV-1 CIRCULATING RECOMBINANT FORMS CRF01_AE AND CRF02_ AG IN BULGARIA , 2020, PROBLEMS of Infectious and Parasitic Diseases.
[15] S. Knyazev,et al. Molecular Epidemiology of the HIV-1 Subtype B Sub-Epidemic in Bulgaria , 2020, Viruses.
[16] M. Poljak,et al. Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia , 2019, Scientific Reports.
[17] M. Poljak,et al. HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011–2016 update , 2018, PloS one.
[18] Kazutaka Katoh,et al. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization , 2017, Briefings Bioinform..
[19] P. Harrigan,et al. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. , 2017, The New England journal of medicine.
[20] M. Nikolova,et al. Origin and spread of HIV-1 in persons who inject drugs in Bulgaria. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[21] Sudhir Kumar,et al. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. , 2016, Molecular biology and evolution.
[22] Jan Albert,et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] J. Nielsen,et al. Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study , 2015, HIV medicine.
[24] A. Wensing,et al. Low HIV-1 transmitted drug resistance in Bulgaria against a background of high clade diversity. , 2015, The Journal of antimicrobial chemotherapy.
[25] Dan Otelea,et al. Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG and Subtype F1 Strains. , 2015, AIDS research and human retroviruses.
[26] Glenn Lawyer,et al. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification , 2014, Nucleic acids research.
[27] Anders Larsson,et al. AliView: a fast and lightweight alignment viewer and editor for large datasets , 2014, Bioinform..
[28] Anne-Mieke Vandamme,et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance , 2013 .
[29] S. Ruță,et al. Transmitted HIV drug resistance in treatment‐naive Romanian patients , 2013, Journal of medical virology.
[30] D. Katzenstein,et al. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. , 2013, The Journal of infectious diseases.
[31] Osamu Nishimura,et al. aLeaves facilitates on-demand exploration of metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivity , 2013, Nucleic Acids Res..
[32] W. Switzer,et al. Detailed Molecular Epidemiologic Characterization of HIV-1 Infection in Bulgaria Reveals Broad Diversity and Evolving Phylodynamics , 2013, PloS one.
[33] Myron S. Cohen,et al. HIV treatment as prevention and HPTN 052. , 2012, Current opinion in HIV and AIDS.
[34] T. Pupko,et al. Emergence of an HIV‐1 cluster harbouring the major protease L90M mutation among treatment‐naïve patients in Tel Aviv, Israel , 2011, HIV medicine.
[35] Matthias Cavassini,et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. , 2010, The Journal of infectious diseases.
[36] Paramvir S. Dehal,et al. FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.
[37] Ming Zhang,et al. jpHMM: Improving the reliability of recombination prediction in HIV-1 , 2009, Nucleic Acids Res..
[38] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[39] Michel Roger,et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection , 2008, AIDS.
[40] Soo-Yon Rhee,et al. Sequence editing by Apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance , 2008, AIDS.
[41] Soo-Yon Rhee,et al. Consensus Drug Resistance Mutations for Epidemiological Surveillance: Basic Principles and Potential Controversies , 2008, Antiviral therapy.
[42] Tulio de Oliveira,et al. High-Resolution Molecular Epidemiology and Evolutionary History of HIV-1 Subtypes in Albania , 2008, PloS one.
[43] V. Carey,et al. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy. , 2002, The Journal of infectious diseases.
[44] L. Bacheler,et al. Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.
[45] J. Schapiro,et al. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. , 2000, The Journal of infectious diseases.
[46] B. Foley,et al. Origin and Spread of HIV-1 Subtype B Among Heterosexual Individuals in Bulgaria. , 2017, AIDS research and human retroviruses.
[47] W. Heneine,et al. Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network. , 2017, Virus evolution.
[48] M. Stanojevic,et al. Ten years survey of primary HIV-1 resistance in Serbia: the occurrence of multiclass resistance. , 2014, AIDS research and human retroviruses.
[49] M. Poljak,et al. HIV‑1 molecular epidemiology in the Balkans: a melting pot for high genetic diversity. , 2012, AIDS reviews.
[50] K. Shadan,et al. Available online: , 2012 .